Bowel perforation from bevacizumab for the management of colorectal cancer

Anti-Cancer Drugs

Volumn 20, Issue SPEC. ISS. 2, 2009, Pages

  Huerta, Sergio ^a   Li, Hsiao C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

Author keywords

Acute abdomen; Adjuvant chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; METASTASIS; NAUSEA; NEUROTOXICITY; PNEUMOPERITONEUM; PRIORITY JOURNAL; PROTEINURIA; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 68049086899     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000349759.64373.e9     Document Type: Article

References (10)

1. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29:10-14.
2. Simpson D, Dunn C, Curran M, Goa KL. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003; 63:2127-2156.
3. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 2006; 63:334-337.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, HeimW, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
5. Kozloff M, Cohn A, Christiansen N, Flynn P, Kabbinavar F, Robles R, et al. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a larger registry in the US [abstract]. J Clin Oncol (Meeting Abstracts) 2005; 23:3566.
6. Fischer L, Kimose HH, Spjeldnaes N, Wara P. Late progress of radiation-induced proctitis. Acta Chir Scand 1990; 156:801-805.
7. Pricolo VE, Shellito PC. Surgery for radiation injury to the large intestine. Variables influencing outcome. Dis Colon Rectum 1994; 37:675-684.
8. Haboubi NY, Schofield PF, Rowland PL. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 1988; 83:1140-1144.
9. Tomori H, Yasuda T, Shiraishi M, Isa T, Muto Y, Egawa H. Radiation-associated ischemic coloproctitis: report of two cases. Surg Today 1999; 29:1088-1092.
10. Skillings JR, Johnson DH, Miller K, Kabbinavar F, Bergsland E, Holmgren E, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy [abstract]. J Clin Oncol (Meeting Abstracts) 2005; 23:3019.